MENU

XTLB Stock Tickeron detected bearish Stock Pattern: Cup-and-Handle Inverse XTLB on September 13, 2024, netting in a 28.67% gain over 1 month

A.I.dvisor
at Tickeron.com
10/17/24
Loading...
+28.67% Gain from a Successful pattern Cup-and-Handle Inverse
XTLB - XTL Biopharmaceuticals Ltd
Ticker: XTLB
Company: XTL Biopharmaceuticals
Gain from shortening: +28.67%
Confirmed: 09/13/24
Succeeded: 10/15/24
Total length: 46 days
On August 30, 2024, A.I.dvisor detected a Cup-and-Handle Inverse Pattern (Bearish) for XTL Biopharmaceuticals Ltd (XTLB, $2.79). 14 days later, on September 13, 2024, A.I.dvisor confirmed the Bearish pattern, setting a target price of the stock. On October 15, 2024, the stock hit the target price of $2.07 – resulting in a +2 gain for traders who shorted the stock on the pattern detection date.

XTLB sees MACD Histogram just turned negative

XTLB saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 30, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 64 instances where the indicator turned negative. In of the 64 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XTLB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for XTLB entered a downward trend on October 11, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XTLB's RSI Indicator exited the oversold zone, of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XTLB advanced for three days, in of 177 cases, the price rose further within the following month. The odds of a continued upward trend are .

XTLB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. XTLB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.845) is normal, around the industry mean (12.582). P/E Ratio (0.000) is within average values for comparable stocks, (110.042). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.002). XTLB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (223.593).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XTLB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
XTLB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutics to treat hepatitis and other infectious diseases, using human antibodies and synthetic chemicals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
5 Badner Street
Phone
+972 36116600
Employees
4
Web
https://www.xtlbio.com